title: Response to: 'belimumab and the measurement of fatigue' by Mazzoni.
authors.affiliation: Division Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA.
authors.forename: V
authors.initials: V
authors.lastname: Strand
authors.affiliation: Department of Medicine, Universidade do Estado do Rio de Janeiro, Brazil.
authors.forename: R A
authors.initials: RA
authors.lastname: Levy
authors.affiliation: Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain.
authors.forename: R
authors.initials: R
authors.lastname: Cervera
authors.affiliation: Department of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA.
authors.forename: M
authors.initials: M
authors.lastname: Petri
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D008297:Male
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents
keywords: Infections; Systemic Lupus Erythematosus; Treatment